1. Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis 
Floor A.C. Berden, Bryan R.R.Z. Aaldering, Hans Groenewoud, Joanna IntHout, Wietske Kievit, Joost P.H. Drenth 
Clinical Gastroenterology and Hepatology 
Volume 15, Issue 3, Pages (March 2017)
DOI: /j.cgh
Copyright © 2017 AGA Institute Terms and Conditions

2. Figure 1
Study selection flow chart summarizing the selection and identification of trials and studies. GT3, genotype 3; SVR12/24, sustained virologic response at 12 or 24 weeks after cessation of treatment.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

3. Figure 2
Networks of studies. Evidence network of all DAA-based regimens studied in chronic hepatitis C genotype 3 patients. The thickness of the lines represents the number of studies (connecting lines) or the total number of patients studied (box lines). Within the box, the DAA combination with the duration of treatment (12, 16, or 24 weeks) is visible. Gray regimens are selected for ranking. DCV, daclatasvir; LDV, ledipasvir; OBV, ombitasvir; PR, peginterferon and ribavirin; PTV, paritaprevir/ritonavir; RBV, ribavirin; SOF, sofosbuvir; TPR, telaprevir; 12, 12 weeks; 16, 16 weeks; 24, 24 weeks; VEL, velpatasvir 100 mg; VEL(25), velpatasvir 25 mg.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

4. Figure 3
Estimated SVR rates per regimen. (A) The mean estimated probability on SVR per regimen with 95% CrI. The SVR rates are estimated for patients without cirrhosis. (B) The mean estimated probability on SVR per regimen with 95% CrI. The SVR rates are estimated for patients with cirrhosis. DCV, daclatasvir; LDV, ledipasvir; OBV, ombitasvir; PR, peginterferon and ribavirin; PTV, paritaprevir/ritonavir; RBV, ribavirin; SOF, sofosbuvir; TPR, telaprevir; 12, 12 weeks; 16, 16 weeks; 24, 24 weeks; VEL, velpatasvir.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions